NDAINJECTIONINJECTABLE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
5/8 — Partial
COLY-MYCIN M (colistimethate) by Pfizer is clinical pharmacology typical serum and urine levels following a single 150 mg dose of coly-mycin m parenteral im or iv in normal adult subjects are shown in figure 1. Approved for cystic fibrosis, pneumonia, bacterial infections. First approved in 1970.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Typical serum and urine levels following a single 150 mg dose of Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in Figure 1. Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2–3…
Indications (3)
Worked on COLY-MYCIN M at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.